CCM
SABSW icon

Context Capital Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Context Capital Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,203
Closed -$38K – 704
2021
Q4 		$38K Buy
24,203
+23,403
+2,925% +$43K ﹤0.01% 489
2021
Q3 		$1K Hold
800
– – ﹤0.01% 470
2021
Q2 		$1K Buy
+800
New +$581 ﹤0.01% 519

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Context Capital Management's SABSW Position: Q1 2022 in Review

Context Capital Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2022, closing a stake of 24,203 shares — an estimated $38K sold.

Context Capital Management first reported a position in SABSW in Q2 2021 and held it in 3 quarters. The position peaked at $38K in Q4 2021. 13 funds tracked by Wall St. Rank hold SABSW as of Q1 2022.

  • Context Capital Management reported no remaining SAB Biotherapeutics Warrant position as of Q1 2022 after selling out during the quarter.
  • Context Capital Management sold 24,203 SAB Biotherapeutics Warrant shares in Q1 2022, an estimated $38K.
  • Context Capital Management first reported a position in SAB Biotherapeutics Warrant in Q2 2021 and held it in 3 quarters.
  • Context Capital Management's SAB Biotherapeutics Warrant position peaked at $38K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2022.

Based on Context Capital Management's 13F filing for Q1 2022, filed 9 May 2022.